Federal Register / Vol. 65, No. 213 / Thursday, November 2, 2000 / Notices 65861

To obtain copies of the supporting

statement and any related forms for the

proposed paperwork collections

referenced above, access HCFA’s Web

Site address at http://www.hcfa.gov/

regs/prdact95.htm, or E-mail your

request, including your address, phone

number, OMB number, and HCFA

document identifier, to

Paperwork@hcfa.gov, or call the Reports

Clearance Office on (410) 786–1326.

Written comments and

recommendations for the proposed

information collections must be mailed

within 60 days of this notice directly to

the HCFA Paperwork Clearance Officer

designated at the following address:

HCFA, Office of Information Services,

Security and Standards Group, Division

of HCFA Enterprise Standards,

Attention: Julie Brown, Room N2–14–

26, 7500 Security Boulevard, Baltimore,

Maryland 21244–1850.

Date: October 24, 2000.

John P. Burke III,

HCFA Reports Clearance Officer, HCFA Office

of Information Services, Security and

Standards Group, Division of HCFA

Enterprise Standards.

[FR Doc. 00–28171 Filed 11–1–00; 8:45 am]

BILLING CODE 4120–03–U

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Health Care Financing Administration

[Document Identifier: HCFA–R–0232]

Agency Information Collection

Activities: Proposed Collection;

Comment Request

AGENCY: Health Care Financing

Administration, HHS.

In compliance with the requirement

of section 3506(c)(2)(A) of the

Paperwork Reduction Act of 1995, the

Health Care Financing Administration

(HCFA), Department of Health and

Human Services, is publishing the

following summary of proposed

collections for public comment.

Interested persons are invited to send

comments regarding this burden

estimate or any other aspect of this

collection of information, including any

of the following subjects: (1) The

necessity and utility of the proposed

information collection for the proper

performance of the agency’s functions;

(2) the accuracy of the estimated

burden; (3) ways to enhance the quality,

utility, and clarity of the information to

be collected; and (4) the use of

automated collection techniques or

other forms of information technology to

minimize the information collection

burden.

Type of Information Collection

Request: Extension; Title of Information

Collection: Supporting Statement for

Medicare Program Integrity Program

Organizational Conflict of Interest

Disclosure Certificate and Supporting

Regulations in 42 CFR 421.310 and

421.312; Form No.: HCFA–R–0232

(OMB# 0938–0723); Use: This

information is used to assess whether

contractors who perform, or who seek to

perform, Medicare Integrity Program

functions, such as medical review, fraud

review or cost audits, have

organizational conflicts of interest and

whether any conflicts have been

resolved. The entities providing the

information will be organizations that

have been awarded, or seek award of, a

Medicare Integrity Program contract;

Frequency: On occasion; Affected

Public: Businesses or other for profit;

Number of Respondents: 10; Total

Annual Responses: 10; Total Annual

Hours: 2,400.

To obtain copies of the supporting

statement and any related forms for the

proposed paperwork collections

referenced above, access HCFA’s Web

Site address at http://www.hcfa.gov/

regs/prdact95.htm, or E-mail your

request, including your address, phone

number, OMB number, and HCFA

document identifier, to

Paperwork@hcfa.gov, or call the Reports

Clearance Office on (410) 786–1326.

Written comments and

recommendations for the proposed

information collections must be mailed

within 60 days of this notice directly to

the HCFA Paperwork Clearance Officer

designated at the following address:

HCFA, Office of Information Services,

Security and Standards Group, Division

of HCFA Enterprise Standards,

Attention: Julie Brown, Room N2–14–

26, 7500 Security Boulevard, Baltimore,

Maryland 21244–1850.

Dated: October 24, 2000.

John P. Burke III,

HCFA Reports Clearance Officer, HCFA Office

of Information Services, Security and

Standards Group, Division of HCFA

Enterprise Standards.

[FR Doc. 00–28172 Filed 11–01–00; 8:45 am]

BILLING CODE 4120–03–U

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Health Resources and Services

Administration

National Vaccine Injury Compensation

Program; List of Petitions Received

AGENCY: Health Resources and Services

Administration, HHS.

ACTION: Notice.

SUMMARY: The Health Resources and

Services Administration (HRSA) is

publishing this notice of petitions

received under the National Vaccine

Injury Compensation Program (‘‘the

Program’’), as required by section

2112(b)(2) of the Public Health Service

(PHS) Act, as amended. While the

Secretary of Health and Human Services

is named as the respondent in all

proceedings brought by the filing of

petitions for compensation under the

Program, the United States Court of

Federal Claims is charged by statute

with responsibility for considering and

acting upon the petitions.

FOR FURTHER INFORMATION CONTACT: For

information about requirements for

filing petitions, and the Program in

general, contact the Clerk, United States

Court of Federal Claims, 717 Madison

Place, N.W., Washington, D.C. 20005,

(202) 219–9657. For information on

HRSA’s role in the Program, contact the

Director, National Vaccine Injury

Compensation Program, 5600 Fishers

Lane, Room 8A–46, Rockville, MD

20857; (301) 443–6593.

SUPPLEMENTARY INFORMATION: The

Program provides a system of no-fault

compensation for certain individuals

who have been injured by specified

childhood vaccines. Subtitle 2 of title

XXI of the PHS Act, 42 U.S.C. 300aa–

10 et seq., provides that those seeking

compensation are to file a petition with

the U.S. Court of Federal Claims and to

serve a copy of the petition on the

Secretary of Health and Human

Services, who is named as the

respondent in each proceeding. The

Secretary has delegated her

responsibility under the Program to

HRSA. The Court is directed by statute

to appoint special masters who take

evidence, conduct hearings as

appropriate, and make initial decisions

as to eligibility for, and amount of,

compensation.

A petition may be filed with respect

to injuries, disabilities, illnesses,

conditions, and deaths resulting from

vaccines described in the Vaccine Injury

Table (the Table) set forth at section

2114 of the PHS Act or as set forth at

42 CFR 100.3, as applicable. This Table

lists for each covered childhood vaccine

the conditions which will lead to

compensation and, for each condition,

the time period for occurrence of the

first symptom or manifestation of onset

or of significant aggravation after

vaccine administration. Compensation

may also be awarded for conditions not

listed in the Table and for conditions

that are manifested after the time

periods specified in the Table, but only

65862 Federal Register / Vol. 65, No. 213 / Thursday, November 2, 2000 / Notices

if the petitioner shows that the

condition was caused by one of the

listed vaccines.

Section 2112(b)(2) of the PHS Act, 42

U.S.C. 300aa–12(b)(2), requires that the

Secretary publish in the Federal

Register a notice of each petition filed.

Set forth below is a list of petitions

received by HRSA on April 3, 2000,

through June 30, 2000.

Section 2112(b)(2) also provides that

the special master ‘‘shall afford all

interested persons an opportunity to

submit relevant, written information’’

relating to the following:

1. The existence of evidence ‘‘that

there is not a preponderance of the

evidence that the illness, disability,

injury, condition, or death described in

the petition is due to factors unrelated

to the administration of the vaccine

described in the petition,’’ and

2. Any allegation in a petition that the

petitioner either:

(a) ‘‘Sustained, or had significantly

aggravated, any illness, disability,

injury, or condition not set forth in the

Table but which was caused by’’ one of

the vaccines referred to in the Table, or

(b) ‘‘Sustained, or had significantly

aggravated, any illness, disability,

injury, or condition set forth in the

Table the first symptom or

manifestation of the onset or significant

aggravation of which did not occur

within the time period set forth in the

Table but which was caused by a

vaccine’’ referred to in the Table.

This notice will also serve as the

special master’s invitation to all

interested persons to submit written

information relevant to the issues

described above in the case of the

petitions listed below. Any person

choosing to do so should file an original

and three (3) copies of the information

with the Clerk of the U.S. Court of

Federal Claims at the address listed

above (under the heading ‘‘For Further

Information Contact’’), with a copy to

HRSA addressed to Associate

Administrator, Bureau of Health

Professions, 5600 Fishers Lane, Room

8–05, Rockville, MD 20857. The Court’s

caption (Petitioner’s Name v. Secretary

of Health and Human Services) and the

docket number assigned to the petition

should be used as the caption for the

written submission.

Chapter 35 of title 44, United States

Code, related to paperwork reduction,

does not apply to information required

for purposes of carrying out the

Program.

List of Petitions

1. Tammy Sharp on behalf of Daniel

Sharp, Houston, Texas, Court of

Federal Claims Number 00–0176V

2. Catherine M. Wucker, Vienna,

Virginia, Court of Federal Claims

Number 00–0179V

3. Maureen E. Carr, Vienna, Virginia,

Court of Federal Claims Number

00–0180V

4. Jennifer K. Duncan, Vienna, Virginia,

Court of Federal Claims Number

00–0181V

5. Jill S. Whetmore-Brown and Michael

Brown on behalf of Michael Brown,

Flower Mound, Texas, Court of

Federal Claims Number 00–0182V

6. Christy and Wesley Duncan on behalf

of Jacob Wesley Duncan, Temple,

Texas, Court of Federal Claims

Number 00–0183V

7. Ellen and Allen Dye on behalf of

Mark Allen Dye, Jr., Berkley

Springs, West Virginia, Court of

Federal Claims Number 00–0184V

8. Patricia and Ira Bonner on behalf of

Jenna Nicole Bonner, Bluffton,

South Carolina, Court of Federal

Claims Number 00–0194V

9. Suzanne Chouinard on behalf of

Julien Chouinard, Boston,

Massachusetts, Court of Federal

Claims Number 00–0196V

10. Margo Ferro on behalf of Nico Ferro,

Scarsdale, New York, Court of

Federal Claims Number 00–0201V

11. Annamma Abraham, Dallas, Texas,

Court of Federal Claims Number

00–0203V

12. Andrea J. Newman, Houlton, Maine,

Court of Federal Claims Number

00–0206V

13. Isabel Salgado, Chicago, Illinois,

Court of Federal Claims Number

00–0219V

14. Jacqueline Chait, Portland, Maine,

Court of Federal Claims Number

00–0224V

15. Helen Harwell on behalf of Mari

Hall, Deceased, Dallas, Texas, Court

of Federal Claims Number 00–

0230V

16. Charron Sayre on behalf of Gabriel

Sayre, Fairborne, Ohio, Court of

Federal Claims Number 00–0231V

17. Nancy Whittington, Lafayette,

Louisiana, Court of Federal Claims

Number 00–0232V

18. Anthony Wright, Amarillo, Texas,

Court of Federal Claims Number

00–0233V

19. Norma Jean Steele on behalf of

Tiffany Jane Steele, Pensacola,

Florida, Court of Federal Claims

Number 00–0235V

20. Ruth and Walter Quiller on behalf of

Timothy Quiller, Augusta, Georgia,

Court of Federal Claims Number

00–0252V

21. Marcy and Michael Tarrants on

behalf of Blake Tarrants, Sedalia,

Missouri, Court of Federal Claims

Number 00–0256V

22. Arthur Beaty on behalf of Sheronda

Beaty, Rochester, New York, Court

of Federal Claims Number 00–

0266V

23. Elaine Pietrucha on behalf of

Bradley Pietrucha, Milford, New

Jersey, Court of Federal Claims

Number 00–0269V

24. Debra Keith Elizabethtown,

Kentucky, Court of Federal Claims

Number 00–0273V

25. Rhonda Rogers on behalf of Nathan

D. Rogers, Lottsburg, Virginia, Court

of Federal Claims Number 00–

0276V

26. Kristen and Patrick Strain on behalf

of Zachary P. Strain, Waterville,

New York, Court of Federal Claims

Number 00–0279V

27. Gina and Carl Geppert on behalf of

Carl Lee Geppart, III, Vienna,

Virginia, Court of Federal Claims

Number 00–0286V

28. Patricia Groht, Vienna, Virginia,

Court of Federal Claims Number

00–0287V

29. Jill and Dugan Dietz on behalf of

Lukas Jackson Dietz, Deceased,

Wheeling, West Virginia, Court of

Federal Claims Number 00–0288V

30. Melynda Slay on behalf of Harrison

Bryce Slay, Aurora, Colorado, Court

of Federal Claims Number 00–

0289V

31. Amanda Fussell on behalf of

Samantha Butts, Deceased, Palm,

California, Court of Federal Claims

Number 00–0309V

32. Jill F. Thigpen, Vienna, Virginia,

Court of Federal Claims Number

00–0319V

33. Firas and Rania Sallaj on behalf of

Zena Sallaj, Buffalo, New York,

Court of Federal Claims Number

00–0321V

34. Kathy and Todd Meena on behalf of

Cameron Todd Meena, Orlando,

Florida, Court of Federal Claims

Number 00–0327V

35. Juan Perez and Irma Hernandez on

behalf of Daphne Perez, Los

Angeles, California, Court of

Federal Claims Number 00–0328V

36. Linda Cook on behalf of Michael

Cook, Vienna, Virginia, Court of

Federal Claims Number 00–0331V

37. Esther Maupins, Lexington,

Kentucky, Court of Federal Claims

Number 00–0332V

38. Joee Jacobs on behalf of Chanz

Jacobs, Bay City, Michigan, Court of

Federal Claims Number 00–0333V

39. Nancy Hilliard on behalf of Owen S.

Hilliard, Ramona, California, Court

of Federal Claims Number 00–

0341V

40. Laurie Ann Amimoto on behalf of

Jacqueline Amimoto, Sacramento,

California, Court of Federal Claims

Number 00–0342V

Federal Register / Vol. 65, No. 213 / Thursday, November 2, 2000 / Notices 65863

41. Kyle Youngberg Ames, Iowa, Court

of Federal Claims Number 00–

0345V

42. Wanda E. Dennis on behalf of Brian

Keith Wingate, Manning, South

Carolina, Court of Federal Claims

Number 00–0346V

43. Tracy and Scott Weeks on behalf of

Jenica Weeks, Deceased, Boston,

Massachusetts, Court of Federal

Claims Number 00–0348V

44. Chue Xiong, Sacramento, California,

Court of Federal Claims Number

00–350V

45. Marion Underwood on behalf of

Cesar Zachary Moreno, Deceased,

Boston, Massachusetts, Court of

Federal Claims Number 00–0357V

46. Ann Haynes on behalf of Elizabeth

Haynes, Boston, Massachusetts,

Court of Federal Claims Number

00–0358V

47. Cynthia Wells on behalf of Ezra

James McCorkle, Boone, North

Carolina, Court of Federal Claims

Number 00–0359V

48. Sandra and William Spoon on behalf

of William Spoon, Phoenix,

Arizona, Court of Federal Claims

Number 00–0360V

49. Kimberly Willingham on behalf of

Courtney Willingham, Rockford,

Illinois, Court of Federal Claims

Number 00–0363V

50. Kristin and Mark Rogers on behalf

of Colin Rogers, Chapel Hill, North

Carolina, Court of Federal Claims

Number 00–0368V

51. Stephanie and Cory Geho on behalf

of Griffin Cole Geho, Portsmouth,

Ohio, Court of Federal Claims

Number 00–0370V

52. Sherri Lynn Boothby, Vienna,

Virginia, Court of Federal Claims

Number 00–0371V

53. Kristin Rogers on behalf of Colin

Rogers, Chapel Hill, North Carolina,

Court of Federal Claims Number

00–0372V

54. Anthony Joseph Tedesco, Clinton

Township, Michigan, Court of

Federal Claims Number 00–0373V

Dated: October 26, 2000.

Claude Earl Fox,

Administrator.

[FR Doc. 00–28136 Filed 11–1–00; 8:45 am]

BILLING CODE 4160–15–U

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Cancer Institute: Opportunity

for a Cooperative Research and

Development Agreement (CRADA) for

the Identification and Development of

Chemical Compounds That Interact

With the Polo-Box of Polo Kinases, as

Potential Therapeutic Targets for the

Inhibition of Cellular Proliferation

AGENCY: National Institutes of Health,

PHS, DHHS

ACTION: Notice.

SUMMARY: Members of the polo

subfamily of protein kinases play

important roles in cell proliferation, and

regulation of polo kinases may be

crucial in the control of cell division.

The polo kinases contain a distinct

region of homology in the C-terminal

non-catalytic domain, termed the polobox. Scientists from the National Cancer

Institute (NCI) have demonstrated that

over-expression of this non-catalytic Cterminal domain in budding yeast

results in a dominant-negative

inhibition of cell division. NCI seeks a

Cooperative Research and Development

Agreement (CRADA) Collaborator to aid

in the identification and development of

chemical compounds that interact with

the polo-box of polo kinases, as

potential therapeutic targets for the

inhibition of cellular proliferation.

DATES: Interested parties should notify

this office in writing of their interest in

filing a formal proposal no later than

January 2, 2000. Potential CRADA

Collaborators will then have an

additional thirty (30) days to submit a

formal proposal. CRADA proposals

submitted thereafter may be considered

if a suitable CRADA Collaborator has

not been selected.

ADDRESSES: Inquires and proposals

regarding this opportunity should be

addressed to Laurie W. Whitney, Ph.D.,

Technology Development Specialist

(Tel: 301–496–0477, FAX: 301–402–

2117), Technology Development and

Commercialization Branch, National

Cancer Institute, 6120 Executive Blvd.,

Suite 450, Rockville, MD 20852.

Inquiries directed to obtaining patent

license(s) needed for participation in the

CRADA opportunity should be

addressed to Vasant Gandhi, J.D., Ph.D.,

Technology Licensing Specialist, Office

of Technology Transfer, National

Institutes of Health, 6011 Executive

Blvd., Suite 325, Rockville, MD 20852,

(Tel: 301–496–7056, ext. 224, FAX: 301–

402–0220).

SUPPLEMENTARY INFORMATION: A

Cooperative Research and Development

Agreement (CRADA) is the anticipated

joint agreement to be entered into with

NCI pursuant to the Federal Technology

Transfer Act of 1986 and Executive

Order 12591 of April 10, 1987 as

amended by the National Technology

Transfer Advancement Act of 1995. NCI

is looking for a CRADA partner to aide

NCI in the identification and

development of chemical compounds

which act as polo-box inhibitors. The

expected duration of the CRADA would

be from one (1) to five (5) years.

Members of the polo subfamily of

protein kinases appear to play pivotal

roles in cell division and proliferation.

These include mammalian Plk, Snk, and

Fnk/Prk, Xenopus laevis Plx1,

Drosophila melanogaster polo,

Schizosaccharomyces pombe Plo1, and

Saccharomyces cerevisiae Cdc5. The

polo subfamily members are

characterized by the presence of a

distinct region of homology in the Cterminal non-catalytic domain, termed

the polo-box, which is essential for

subcellular localization and mitotic

functions of the polo kinases.

Regulation of polo kinases may be

crucial in the control of cell division. In

mammalian cells, Plk is expressed at

high levels in mitotically active cells

and in tumors of various origins.

Constitute expression of Plk in NIH3T3

cells induces oncogenic focus

formation, and these Plk-transformed

cells can form tumors in nude mice.

These data suggest that Plk expression

is closely related to cellular

proliferation, and that uncontrolled Plk

expression may lead to the development

of cancers in humans. Genetic and

biochemical analyses indicate that polo

kinases regulate diverse cellular events

at various stages of the M phase. In

addition to their roles in spindle

formation and centrosome maturation,

polo kinases appear to regulate

important biochemical steps at the G2/

M transition, such as activation of Cdc2

through Cdc25C phosphatase, DNA

damage checkpoint adaptation, and

activation of the anaphase-promoting

complex (APC) in various eukaryotic

systems. In addition, recent data suggest

that polo kinases play important roles in

cytokinesissea.

In budding yeast, overexpression of

the non-catalytic C-terminal domain of

either Plk or Cdc5 (plk∆N or cdc5∆N),

but not the corresponding polo-box

mutant, results in severe connected cell

morphology. Provision of functional

Cdc5 remedies this phenotype,

indicating that over-expression of

cdc5∆N or plk∆N results in a dominantnegative inhibition of cell division and